Sodium phenylbutyrate - Lucane Pharma

Drug Profile

Sodium phenylbutyrate - Lucane Pharma

Alternative Names: Luc-01; Pheburane; Phenylbutyrate - Lucane Pharma

Latest Information Update: 06 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lucane Pharma
  • Developer Lucane Pharma; Medunik Canada
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia

Most Recent Events

  • 06 Jun 2017 No recent reports on development identified - Registered for Hyperammonaemia (Adjunctive treatment) in Iceland and Liechtenstein (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 30 Mar 2015 Launched for Hyperammonaemia (Adjunctive treatment in patients with urea cycle disorders) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top